BioGene is developing and validating assays for human applications on the CENOS™ platform focusing on the detection of High Consequence Infectious Diseases.
- Designed for multiplex capability.
- Optimised for crude sample workflows.
- Configured for decentralised deployment beyond the laboratory.
- Influenza A / B
- SARS-CoV-2
- RSV
- Emerging respiratory threats
- Filoviruses (Ebola, Marburg)
- Arenaviruses (Lassa)
- Emerging high-consequence haemorrhagic agents
- Norovirus
- Rotavirus
- Enteric adenoviruses
- Emerging gastrointestinal threats